Freeline Therap

$2.25 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Freeline Therap

Freeline Therapeutics Holdings plc is a clinical-stage systemic adeno-associated viruses (AAV)-based gene therapy company. The Company focuses to deliver one-time gene therapy treatments that provide functional cures through permanently sustained physiological protein levels, leveraging the expression enabled by its gene therapy platform. Its gene therapy product candidates target the liver in order to cause the production of proteins that are released in the bloodstream at levels sufficient to have a therapeutic benefit. The Company’s platform includes capsid and promoter, research tools and capabilities, and manufacturing. It manufactures the product candidates using its split-plasmid system running in the iCELLis adherent mammalian cell production system. Its product candidates include FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease, FLT201 for the treatment of Gaucher disease and FLT210 for the treatment of hemophilia A.

Stock Analysis

last close $2.25
1-mo return -28.6%
3-mo return -42.7%
avg daily vol. 139.45T
52-week high 18.88
52-week low 2.15
market cap. $83M
forward pe -
annual div. -
roe -60.4%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 30.2%

Subscribe now for daily local and international financial news